吸入依洛前列环素对先天性心脏病继发肺动脉高压患者的急性血管扩张试验

Acute dilatation test of aerosolized iloprost in pulmonary hypertension patients with congenital heart diseaseAcute dilatation test of aerosolized iloprost in pulmonary hypertension patients with congenital heart disease

目的探讨吸入依洛前列环素（iloprost）对先天性心脏病（CHD）继发肺动脉高压（PAH）患者的肺动脉压力（PAP）、肺血管阻力（PVR）、心指数（CI）的影响。方法给予34例CHD继发PAH患者吸入iloprost和生理盐水，分别测量吸入iloprost和生理盐水后肺动脉收缩压（SPAP）、肺动脉舒张压（DPAP）、肺动脉平均压（MPAP）、PVR，CI、体循环平均压（MAP）和心率（HR），比较两组指标的差异。结果吸入iloprost后PAH患者的SPAP、DPAP、MPAP和PVR下降，CI增加，MAP、HR无明显变化。结论吸入iloprost可安全有效地降低PAH患者的PAP和PVR，增加CI。

Objective To investigate the effects of PAP, PVR, CI after inhaling iloprost in congenital heart disease（CHD） with pulmonary artery hypertension（PAH）. Methods Before and after inhaling sodium chloride liquid or inhaling iloprost, SPAP, DPAP, MPAP, PVR, CI, MAP, HR were measured respectively in 34 CHD patients with PAH, then all the parameters were compared. Results Iloprost can decrease SPAP, DPAP, MPAP, PVR and increase CI, but has no significant influence on MAP and HR. Conclusion Aerosolized iloprost is safely and effectively in decreasing PAP, PVR and increase CI.